MX2020012900A - Potentes inhibidores de d-aminoacido oxidasa (daao) y sus usos. - Google Patents

Potentes inhibidores de d-aminoacido oxidasa (daao) y sus usos.

Info

Publication number
MX2020012900A
MX2020012900A MX2020012900A MX2020012900A MX2020012900A MX 2020012900 A MX2020012900 A MX 2020012900A MX 2020012900 A MX2020012900 A MX 2020012900A MX 2020012900 A MX2020012900 A MX 2020012900A MX 2020012900 A MX2020012900 A MX 2020012900A
Authority
MX
Mexico
Prior art keywords
daao
amino acid
acid oxidase
potent inhibitors
formula
Prior art date
Application number
MX2020012900A
Other languages
English (en)
Inventor
Guochuan Emil Tsai
Ching - Cheng WANG
Tien - Lan Hsieh
Ming - Hong Chien
Original Assignee
Syneurx Int Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syneurx Int Taiwan Corp filed Critical Syneurx Int Taiwan Corp
Publication of MX2020012900A publication Critical patent/MX2020012900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se proporcionan potentes compuestos de la Fórmula (I) y usos de estos para inhibir la actividad de la D-aminoácido oxidasa (DAAO) o para tratar enfermedades o trastornos asociados con DAAO, tales como un trastorno del sistema nervioso central (CNS), dolor, obesidad, diabetes o hiperlipidemia; también se proporcionan en la presente divulgación métodos para sintetizar los compuestos de la Fórmula (I) descritos en la presente. (ver Fórmula).
MX2020012900A 2018-05-29 2019-05-29 Potentes inhibidores de d-aminoacido oxidasa (daao) y sus usos. MX2020012900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/991,710 US10927138B2 (en) 2018-05-29 2018-05-29 Inhibitors of D-amino acid oxidase (DAAO) and uses thereof
PCT/CN2019/089044 WO2019228408A1 (en) 2018-05-29 2019-05-29 Potent inhibitors of d-amino acid oxidase (daao) and uses thereof

Publications (1)

Publication Number Publication Date
MX2020012900A true MX2020012900A (es) 2021-02-26

Family

ID=68695163

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012900A MX2020012900A (es) 2018-05-29 2019-05-29 Potentes inhibidores de d-aminoacido oxidasa (daao) y sus usos.

Country Status (11)

Country Link
US (2) US10927138B2 (es)
EP (1) EP3802478A4 (es)
JP (1) JP2021525751A (es)
KR (1) KR20210015837A (es)
CN (1) CN112566894A (es)
BR (1) BR112020024164B1 (es)
CA (1) CA3101664A1 (es)
IL (1) IL278975A (es)
MX (1) MX2020012900A (es)
TW (2) TWI755601B (es)
WO (1) WO2019228408A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
EP4104860A4 (en) 2020-02-10 2024-03-06 Exostemtech Co Ltd EXOSOME WITH LIGHT-SPLITABLE PROTEIN AND USE THEREOF
CN115836062A (zh) * 2020-04-23 2023-03-21 心悦生医股份有限公司 化合物及其医药用途
CN111493026B (zh) * 2020-04-30 2022-03-29 苏州必睿康医药科技有限公司 2型糖尿病非人动物模型的构建方法，及所得动物的应用
EP3960168A1 (en) 2020-08-28 2022-03-02 Université de Genève Compositions and methods comprising d-cysteine or a derivative thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559105A1 (en) * 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Benzisoxazoles
US7907499B2 (en) 2006-07-26 2011-03-15 Konica Minolta Holdings, Inc. Optical element, optical element manufacturing method and optical pickup device
WO2008131047A2 (en) * 2007-04-16 2008-10-30 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
CA2794266C (en) * 2010-03-24 2020-09-08 Ohio University Compositions and methods for glucose transport inhibition
US20130164228A1 (en) * 2011-12-21 2013-06-27 Colgate-Palmolive Company Compositions comprising gallates and gallamides
WO2016146026A1 (en) * 2015-03-13 2016-09-22 China Medical University Method of increasing d-serine concentration and improving cognitive disorders
RU2715703C1 (ru) * 2016-03-28 2020-03-03 Сайньюрекс Интернэшнл (Тайвань) Корп. Композиции, содержащие дубильные кислоты и их применение
WO2017216813A1 (en) * 2016-06-18 2017-12-21 Chigurupati Harsha Composition to reduce dna and hepatic damage and to enhance repair thereof
CN111465400A (zh) * 2017-12-07 2020-07-28 心悦生医股份有限公司 用于制备鞣酸组合物的改良的富集方法

Also Published As

Publication number Publication date
US20190367549A1 (en) 2019-12-05
BR112020024164A2 (pt) 2021-03-02
US20210214385A1 (en) 2021-07-15
EP3802478A4 (en) 2022-09-28
TWI755601B (zh) 2022-02-21
TW202212318A (zh) 2022-04-01
TW202002960A (zh) 2020-01-16
KR20210015837A (ko) 2021-02-10
CA3101664A1 (en) 2019-12-05
US10927138B2 (en) 2021-02-23
EP3802478A1 (en) 2021-04-14
BR112020024164B1 (pt) 2022-11-29
JP2021525751A (ja) 2021-09-27
CN112566894A (zh) 2021-03-26
IL278975A (en) 2021-01-31
WO2019228408A1 (en) 2019-12-05
TWI771246B (zh) 2022-07-11

Similar Documents

Publication Publication Date Title
MX2020012900A (es) Potentes inhibidores de d-aminoacido oxidasa (daao) y sus usos.
MX2022001295A (es) Inhibidores de kif18a.
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2021013146A (es) Inhibidores de receptores del factor de crecimiento de fibroblastos (fgfr) y metodos de uso de los mismos.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
PH12020551170A1 (en) Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
MY197064A (en) Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
PH12020550442A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CA3082254A1 (en) Heterocyclic compounds as kinase inhibitors
PH12020550228A1 (en) Epidermal growth factor receptor inhibitors
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2016016050A (es) Procesos para la preparacion de analogos de oxitocina.
MX2022005084A (es) Formas sólidas de un modulador del receptor s1p a.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2022005085A (es) Procesos para preparar un modulador del receptor s1p.
MX2020012292A (es) Compuestos para el tratamiento de cáncer de pancreas.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor